YAP1 and pancreatic adenocarcinoma: Further analyses showed that YAP1 expression was positively correlated to a wide range of immune checkpoints, especially in PAAD, PCPG, and PRAD, suggesting that YAP1 is a potential new drug target for anti-cancer immunotherapy in these cancer types.